Earnings Call · Q2 FY2024·2024-08-10

Q2 24EPS -0.81%·Rev n/aQ1 24EPS +9.02%·Rev n/aQ4 23EPS -28.70%·Rev n/aQ3 23EPS +20.83%·Rev n/a⚠ consensus missing

Phathom Pharmaceuticals, Inc. PHAT

Eric Sciorilli — Head of Investor Relations

Terrie Curran — President and CEO

Martin Gilligan — Chief Commercial Officer

Molly Henderson — Chief Financial Officer

+8.7%1d on move date+6.4% vs SPY3d+11.3%5d+15.1%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more PHAT calls or request research access.

More PHAT calls Browse calls Request research access